177Lu-LNC1010 / Dongcheng Pharma |
NCT05410743: Evaluation of 177Lu-TATE-EB-01(LNC1010)in SSTR2-positive Tumors |
|
|
| Recruiting | 1/2 | 30 | RoW | 177Lu-LNC1010 1, 177Lu-LNC1010 2, 177Lu-LNC1010 3, 177Lu-LNC1010 4 | The First Affiliated Hospital of Xiamen University | SSTR2-positive Tumors | 12/24 | 12/24 | | |
177Lu-LNC1003 / Dongcheng Pharma |
NCT06237491: The Safety and Dosimetry Study of 177Lu-LNC1003 Injection |
|
|
| Not yet recruiting | 1 | 12 | NA | 177Lu-LNC1003 Injection group 1, 177Lu-LNC1003 Injection group 2, 177Lu-LNC1003 Injection group 3 | Yantai LNC Biotechnology Singapore PTE. LTD. | Metastatic Castration-resistant Prostate Cancer, mCRPC | 11/25 | 12/25 | | |
NCT05613738: 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Recruiting | N/A | 9 | RoW | 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01, 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 | Peking Union Medical College Hospital | Metastatic Castration-resistant Prostate Cancer | 06/25 | 11/25 | | |
ChiCTR2200065809: An exploratory study of 177Lu-PSMA-EB-01 in patients with prostate specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer |
|
|
| Recruiting | N/A | 30 | | Dose 60mCi 177Lu-PSMA-EB-01 ;Dose 100mCi 177Lu-PSMA-EB-01 | The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University, Self-funded | prostate cancer | | | | |
177Lu-LNC1004 / Dongcheng Pharma |
| Not yet recruiting | 2 | 35 | Europe | 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy | Institut Curie | Pancreatic Ductal Adenocarcinoma (PDAC) | 01/29 | 01/30 | | |
NCT05400967: Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI |
|
|
| Recruiting | 1 | 10 | RoW | 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy | Peking Union Medical College Hospital | 177Lu-EB-FAPI | 01/25 | 04/25 | | |
CISPD-5, NCT06081322: A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors |
|
|
| Recruiting | 1 | 29 | RoW | PRRT with 177Lu-EB-FAPI | Zhejiang University | Advanced Pancreatic Cancer and Cholangiocarcinoma | 06/24 | 06/25 | | |
NCT05723640: The Safety and Dosimetry Study of 177Lu-LNC1004 Injection |
|
|
| Recruiting | 1 | 24 | RoW | 177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy, 177Lu-LNC1004 Injection group 4 radionuclide therapy | Yantai LNC Biotechnology Singapore PTE. LTD. | Solid Tumor, Unspecified, Adult | 03/25 | 03/25 | | |